How should I transition a patient from Tresiba (insulin degludec) to Toujeo (insulin glargine U‑300), including initial dose and titration guidance?

Switching from Tresiba to Toujeo

When switching from Tresiba (insulin degludec) to Toujeo (insulin glargine U-300), convert unit-to-unit at the same total daily dose, administer Toujeo at the same time of day as the previous Tresiba injection, and monitor glucose closely during the first several weeks with dose adjustments as needed. 1

Initial Conversion Approach

Use a 1:1 (unit-to-unit) dose conversion when switching from Tresiba to Toujeo, maintaining the same total daily basal insulin dose that the patient was receiving. 2, 3 This straightforward approach is supported by clinical practice patterns, though the pharmacokinetic differences between these insulins require vigilant monitoring.

Key Pharmacokinetic Considerations

• Tresiba has an ultra-long half-life (>42 hours) and takes approximately 3-4 days to reach steady state, meaning insulin will continue to be present in the system for several days after discontinuation 3
• Toujeo has a duration of action of approximately 24-36 hours, which is shorter than Tresiba but longer than first-generation basal insulins 1, 4
• Risk of insulin stacking exists during the transition period due to overlapping pharmacokinetics, particularly in the first 3-5 days 3

Monitoring Protocol

Implement intensive glucose monitoring for at least 2-4 weeks after the switch:

• Check fasting plasma glucose daily to assess basal insulin adequacy 5
• Monitor for hypoglycemia, especially during the first week when both insulins may overlap 3, 4
• Set a fasting plasma glucose target (typically 80-130 mg/dL) to guide titration 5, 2

Titration Strategy

After the initial switch, titrate Toujeo based on fasting glucose readings:

• Increase by 2-4 units once or twice weekly if fasting glucose remains above target 5, 2
• For hypoglycemia without clear cause, reduce dose by 10-20% 5
• Continue titration until fasting plasma glucose consistently reaches the individualized target range 5, 2

Dose Adjustments During Transition

• If the patient was on a very high dose of Tresiba (>0.5 units/kg/day), consider reducing the initial Toujeo dose by 10-20% to account for potential insulin stacking, then uptitrate as needed 3
• If hypoglycemia occurs in the first 3-5 days, this may reflect overlapping insulin action rather than excessive Toujeo dosing; temporary dose reduction may be warranted 3

Administration Details

Toujeo must be administered subcutaneously once daily at the same time each day (can be any time, but consistency is critical). 1 Rotate injection sites between abdomen, thigh, and deltoid to reduce lipodystrophy risk. 1 Never dilute or mix Toujeo with any other insulin or solution. 1

Common Pitfalls to Avoid

• Do not assume immediate steady-state with Toujeo: While Tresiba takes 3-4 days to wash out, Toujeo requires several days to reach its own steady state 3, 4
• Avoid overbasalization: If fasting glucose targets are not achieved despite doses approaching 0.5-1.0 units/kg/day, consider adding prandial insulin or intensifying other glucose-lowering therapies rather than continuing to escalate basal insulin indefinitely 2
• Do not neglect patient education: Ensure patients understand they are switching insulins, check labels before injection to prevent medication errors, and know how to recognize and treat hypoglycemia 1, 3

Special Circumstances

If the patient is hospitalized or acutely ill during the transition, the switch becomes more complex due to unpredictable insulin requirements and the long pharmacokinetic profiles of both insulins. 4 In such cases, consider delaying the switch until the patient is stable, or use shorter-acting insulins temporarily with more frequent monitoring. 4

Prescribe glucagon for emergency hypoglycemia treatment when initiating or switching basal insulins. 5